Skip to main content
ASTH
NASDAQ Trade & Services

Astrana Health Seeks Shareholder Approval for 1 Million Share Increase in Equity Incentive Plan

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
7
Price
$30.6
Mkt Cap
$1.535B
52W Low
$18.08
52W High
$34.8
Market data snapshot near publication time

summarizeSummary

Astrana Health, Inc. filed its definitive proxy statement for its 2026 Annual Meeting, seeking shareholder approval for the re-election of nine directors, ratification of its auditor, an advisory vote on executive compensation, and a significant increase of 1,000,000 shares to its 2024 Equity Incentive Plan.


check_boxKey Events

  • Equity Plan Expansion Proposed

    Shareholders will vote on increasing the 2024 Equity Incentive Plan by 1,000,000 shares, raising the total to 5,100,000 shares. This represents a potential dilution of approximately 1.79% of current outstanding shares.

  • Director Re-election

    Nine incumbent directors are nominated for re-election to the Board until the 2027 Annual Meeting.

  • Executive Compensation Advisory Vote

    An advisory, non-binding vote on executive compensation for named executive officers is on the agenda, following 91% approval in 2025.

  • Auditor Ratification

    Shareholders will vote to ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.


auto_awesomeAnalysis

The most impactful proposal in this definitive proxy statement is the request to increase the share reserve for the 2024 Equity Incentive Plan by 1,000,000 shares, raising the total to 5,100,000 shares. This represents a potential dilution of approximately 1.79% based on the 55,713,532 current outstanding shares, which is a notable amount for future equity awards and could create an overhang on the stock. While such plans are crucial for attracting and retaining talent, the potential dilution is a key consideration for investors. Other proposals, including the re-election of nine incumbent directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation, are routine annual governance matters. The filing also details various related party transactions and confirms the company's insider trading and hedging policies, including a previously approved pledge of shares by the CEO.

At the time of this filing, ASTH was trading at $30.60 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.08 to $34.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ASTH - Latest Insights

ASTH
Apr 17, 2026, 6:01 AM EDT
Filing Type: DEF 14A
Importance Score:
7
ASTH
Mar 30, 2026, 7:39 PM EDT
Filing Type: S-3ASR
Importance Score:
7
ASTH
Mar 30, 2026, 5:43 PM EDT
Source: Wiseek News
Importance Score:
7
ASTH
Mar 12, 2026, 8:11 AM EDT
Filing Type: 10-K
Importance Score:
9
ASTH
Mar 02, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
ASTH
Jan 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7